BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 7813622)

  • 1. Molecular characterization of a type I serine-threonine kinase receptor for TGF-beta and activin in the rat pituitary tumor cell line GH3.
    Takumi T; Moustakas A; Lin HY; Lodish HF
    Exp Cell Res; 1995 Jan; 216(1):208-14. PubMed ID: 7813622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
    Alexander JM; Bikkal HA; Zervas NT; Laws ER; Klibanski A
    J Clin Endocrinol Metab; 1996 Feb; 81(2):783-90. PubMed ID: 8636304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family.
    He WW; Gustafson ML; Hirobe S; Donahoe PK
    Dev Dyn; 1993 Feb; 196(2):133-42. PubMed ID: 8395914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. zALK-8, a novel type I serine/threonine kinase receptor, is expressed throughout early zebrafish development.
    Yelick PC; Abduljabbar TS; Stashenko P
    Dev Dyn; 1998 Apr; 211(4):352-61. PubMed ID: 9566954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of rat transforming growth factor-beta type II receptor.
    Tsuchida K; Lewis KA; Mathews LS; Vale WW
    Biochem Biophys Res Commun; 1993 Mar; 191(3):790-5. PubMed ID: 8385453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.
    Lewis KA; Gray PC; Blount AL; MacConell LA; Wiater E; Bilezikjian LM; Vale W
    Nature; 2000 Mar; 404(6776):411-4. PubMed ID: 10746731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI.
    Onichtchouk D; Chen YG; Dosch R; Gawantka V; Delius H; Massagué J; Niehrs C
    Nature; 1999 Sep; 401(6752):480-5. PubMed ID: 10519551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mouse TGF-beta type I receptor that requires type II receptor for ligand binding.
    Suzuki A; Shioda N; Maeda T; Tada M; Ueno N
    Biochem Biophys Res Commun; 1994 Feb; 198(3):1063-9. PubMed ID: 8117262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The conventional transforming growth factor-beta (TGF-beta) receptor type I is not required for TGF-beta 1 signaling in a human prostate cancer cell line, LNCaP.
    Kim IY; Zelner DJ; Lee C
    Exp Cell Res; 1998 May; 241(1):151-60. PubMed ID: 9633523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and developmental expression of two activin receptors in baboon lung.
    Zhao Y; Silbajoris R; Young SL
    Biochem Biophys Res Commun; 1996 Dec; 229(1):50-7. PubMed ID: 8954082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular smooth muscle cells express multiple type I receptors for TGF-beta, activin, and bone morphogenetic proteins.
    Agrotis A; Samuel M; Prapas G; Bobik A
    Biochem Biophys Res Commun; 1996 Feb; 219(2):613-8. PubMed ID: 8605036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity.
    ten Dijke P; Ichijo H; Franzén P; Schulz P; Saras J; Toyoshima H; Heldin CH; Miyazono K
    Oncogene; 1993 Oct; 8(10):2879-87. PubMed ID: 8397373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A WD-domain protein that is associated with and phosphorylated by the type II TGF-beta receptor.
    Chen RH; Miettinen PJ; Maruoka EM; Choy L; Derynck R
    Nature; 1995 Oct; 377(6549):548-52. PubMed ID: 7566156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.
    Greenwald J; Fischer WH; Vale WW; Choe S
    Nat Struct Biol; 1999 Jan; 6(1):18-22. PubMed ID: 9886286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
    Guo Y; Kyprianou N
    Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cloning, genetic mapping, and developmental expression of a bovine transforming growth factor beta (TGF-beta) type I receptor.
    Roelen BA; Van Eijk MJ; Van Rooijen MA; Bevers MM; Larson JH; Lewin HA; Mummery CL
    Mol Reprod Dev; 1998 Jan; 49(1):1-9. PubMed ID: 9406190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
    Horie K; Yamashita H; Mogi A; Takenoshita S; Miyazono K
    J Cell Physiol; 1998 Jun; 175(3):305-13. PubMed ID: 9572475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of TGF-beta superfamily receptors in dental pulp.
    Toyono T; Nakashima M; Kuhara S; Akamine A
    J Dent Res; 1997 Sep; 76(9):1555-60. PubMed ID: 9294489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of transforming growth factor beta 1 and its receptor expression during myeloid leukemia cell differentiation.
    Taipale J; Matikainen S; Hurme M; Keski-Oja J
    Cell Growth Differ; 1994 Dec; 5(12):1309-19. PubMed ID: 7696179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH3 pituitary tumor cells contain heteromeric type I and type II receptor complexes for transforming growth factor beta and activin-A.
    Moustakas A; Takumi T; Lin HY; Lodish HF
    J Biol Chem; 1995 Jan; 270(2):765-9. PubMed ID: 7822308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.